Efficacy of Single-Pill Combination of Telmisartan 80 mg and Hydrochlorothiazide 25 mg in Patients with Cardiovascular Disease Risk Factors : A Prospective Subgroup Analysis of a Randomized, Double-Blind, and Controlled Trial
Joint Authors
Völker, Birgit
Ruilope, Luis M.
Bays, Harold
Zhu, Dingliang
Mattheus, Michaela
Gao, Pingjin
Source
International Journal of Hypertension
Issue
Vol. 2013, Issue 2013 (31 Dec. 2013), pp.1-13, 13 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2013-04-04
Country of Publication
Egypt
No. of Pages
13
Main Subjects
Abstract EN
Objective.
Report of prespecified and post hoc subgroup analyses of a randomized, controlled trial comparing telmisartan 80 mg/hydrochlorothiazide 25 mg (T80/H25) combination therapy with T80 monotherapy, according to the presence of cardiovascular disease (CVD) risk factors.
Methods.
Hypertensive patients were randomized (2 : 1) to receive T80/H25 or T80 for 6 weeks, following a 1-week, low-dose, and run-in period.
Systolic blood pressure (SBP) and diastolic BP reductions and BP goal achievement were evaluated in patients with CVD risk factors: presence of diabetes mellitus (DM), renal impairment, increased body mass index (BMI), and 10-year estimated risk for coronary heart disease (CHD).
Results.
In total, 888 patients received treatment.
Overall, T80/H25 therapy significantly reduced SBP more than T80 monotherapy, irrespective of patient subgroup.
In patients with DM, renal impairment, high BMI, and high CHD risk, BP goal achievement rates (<140/90 mm Hg) at Week 7, among those treated with T80/H25, were 52.8%, 52.8%, 50.6%, and 38.5%, respectively.
More patients with DM reached a guideline-based BP goal (<130/80 mm Hg) at 7 weeks with T80/H25 than with T80 monotherapy (16.7% versus 8.8%).
Rates of treatment-related adverse events were low and comparable across patient subgroups.
Conclusions.
Antihypertensive treatment with T80/H25 single-pill combination is effective and generally well tolerated, irrespective of the presence of CVD risk factors.
American Psychological Association (APA)
Bays, Harold& Gao, Pingjin& Völker, Birgit& Mattheus, Michaela& Ruilope, Luis M.& Zhu, Dingliang. 2013. Efficacy of Single-Pill Combination of Telmisartan 80 mg and Hydrochlorothiazide 25 mg in Patients with Cardiovascular Disease Risk Factors : A Prospective Subgroup Analysis of a Randomized, Double-Blind, and Controlled Trial. International Journal of Hypertension،Vol. 2013, no. 2013, pp.1-13.
https://search.emarefa.net/detail/BIM-495719
Modern Language Association (MLA)
Bays, Harold…[et al.]. Efficacy of Single-Pill Combination of Telmisartan 80 mg and Hydrochlorothiazide 25 mg in Patients with Cardiovascular Disease Risk Factors : A Prospective Subgroup Analysis of a Randomized, Double-Blind, and Controlled Trial. International Journal of Hypertension No. 2013 (2013), pp.1-13.
https://search.emarefa.net/detail/BIM-495719
American Medical Association (AMA)
Bays, Harold& Gao, Pingjin& Völker, Birgit& Mattheus, Michaela& Ruilope, Luis M.& Zhu, Dingliang. Efficacy of Single-Pill Combination of Telmisartan 80 mg and Hydrochlorothiazide 25 mg in Patients with Cardiovascular Disease Risk Factors : A Prospective Subgroup Analysis of a Randomized, Double-Blind, and Controlled Trial. International Journal of Hypertension. 2013. Vol. 2013, no. 2013, pp.1-13.
https://search.emarefa.net/detail/BIM-495719
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-495719